International journal of clinical oncology
-
Int. J. Clin. Oncol. · Dec 2018
Primary prophylactic granulocyte colony-stimulating factor according to ASCO guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
The efficacy of primary prophylactic granulocyte colony-stimulating factor (G-CSF) in preventing febrile neutropenia (FN) in patients treated with docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy remains controversial. We compared the incidence of FN in patients treated with and without primary prophylactic G-CSF. ⋯ Primary prophylactic G-CSF from day 7 of the first cycle of TPF did not reduce the incidence of FN. Our findings suggest that the timing of primary prophylactic G-CSF, as recommended by the American Society of Clinical Oncology guidelines, should be modified to reduce the incidence of FN in TPF.
-
Int. J. Clin. Oncol. · Oct 2018
The predictors and oncological outcomes of repeat surgery for recurrence after hepatectomy for colorectal liver metastases.
Although recurrence after hepatectomy for colorectal liver metastases (CRLM) is common, the optimal treatment strategy remains unclear. The aims of this study were to clarify the impact of repeat surgery and identify the predictive factors for repeat surgery. ⋯ Repeat surgery for not only intrahepatic but also extrahepatic recurrence is crucial for prolonging the survival of CRLM patients. The proposed model may help to predict the possibility of repeat surgery and provide optimal individualized treatment.
-
Int. J. Clin. Oncol. · Oct 2018
Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer.
The role of adjuvant chemotherapy has not yet been established for patients with resected biliary tract cancer. S-1 has been shown to exert activity against advanced biliary tract cancer. Therefore, we evaluated the feasibility of adjuvant chemotherapy with S-1 in patients with resected biliary tract cancer. ⋯ Adjuvant chemotherapy with S-1 is feasible treatment in patients with resected biliary tract cancer. It is necessary to conduct a phase III study to confirm the efficacy of adjuvant therapy of S-1 in patients with resected BTC.
-
Int. J. Clin. Oncol. · Aug 2018
ReviewRecent advances in medical therapy for metastatic urothelial cancer.
Cytotoxic chemotherapy has been the mainstay of medical therapy for metastatic urothelial cancer. Currently, the gemcitabine/cisplatin regimen is widely used worldwide as the standard first-line medical treatment. ⋯ The paradigm of medical treatment for patients with metastatic UC is dramatically changing through the introduction of this and other immune-checkpoint inhibitors. In this article, we provide a brief overview of these immune-checkpoint inhibitors and a comprehensive summary of the use of cytotoxic chemotherapy for metastatic urothelial cancer, including ongoing clinical trials.
-
Int. J. Clin. Oncol. · Aug 2018
Hibernation of masses suspected to be remnant tumors after surgical resection of retroperitoneal liposarcoma is related to improved overall survival.
Although complete surgical resection is considered the best treatment for retroperitoneal liposarcoma, it is related to a high local recurrence rate. This study analyzed patterns of recurrence of retroperitoneal liposarcoma. ⋯ Hibernation of a recurrence-suspected mass was related to improvement of overall survival in patients with a mass detected within 6 months. This specific patient group should be monitored with care to see if the size of the mass increases. When a mass seemed to be hibernating, a favorable prognosis could be expected.